Alzheimer’s Breakthroughs: Why New Drugs Spark Global Regulatory Debates
Global regulatory bodies, including the FDA and EMA, remain deeply divided over the approval of anti-amyloid monoclonal antibodies for Alzheimer’s disease. While these drugs demonstrate a modest reduction in cognitive ... Read More